Hematologic modifications in natalizumab-treated multiple sclerosis patients: An 18-month longitudinal study

BRIDEL, Claire et al. Hematologic modifications in natalizumab-treated multiple sclerosis patients: An 18-month longitudinal study. In: Neurology® neuroimmunology & neuroinflammation, 2015, vol. 2, n° 4, p. e123. doi: 10.1212/NXI.0000000000000123

Article (Published version)

Identifiers

PID : unige:84046
DOI : 10.1212/NXI.0000000000000123
PMID : 26140281

Journal ISSN2332-7812

441views

288downloads

Creation01/27/2016 11:50:00 AM

First validation01/27/2016 11:50:00 AM

Update time03/15/2023 12:23:50 AM

Status update03/15/2023 12:23:50 AM

Last indexation10/31/2024 3:30:53 AM

Archive ouverte UNIGE

Hematologic modifications in natalizumab-treated multiple sclerosis patients: An 18-month longitudinal study

To monitor the hematologic modifications in the peripheral blood of patients with relapsing-remitting multiple sclerosis treated with natalizumab.

Technical informations